Research in practice: towards deciphering the role of epidermal proteases in recessive dystrophic epidermolysis bullosa progression
Abstract: Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable severe skin disease caused by loss of collagen VII, an extracellular protein that ensures skin cohesion. It manifests in skin blistering and unresolved cycles of wounding and healing that progressively lead to dermal stiffening and early development of aggressive cutaneous squamous cell carcinomas. Inflammation and subsequent tissue fibrosis highly contribute to RDEB pathogenicity and targeting them could provide new therapeutic options. Kallikreins (KLKs) are epidermal secreted proteases, which contribute to skin desquamation and inflammation. Kallikreins are involved in the pathogenesis of several inflammatory skin disorders, but interestingly also in the initiation and progression of different cancers. Our project aims at deciphering the role of KLKs in inflammation, fibrosis, and tumor development in RDEB
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. - 19, 6 (2021) , 828-832, ISSN: 1610-0387
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2021
- Urheber
- DOI
-
10.1111/ddg.14396
- URN
-
urn:nbn:de:bsz:25-freidok-1947537
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nauroy, Pauline
- Zingkou, Eleni
- Sotiropoulou, Georgia
- Kiritsi, Dimitra
- Universität
Entstanden
- 2021
Ähnliche Objekte (12)
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
STAT3 targeting in dystrophic epidermolysis bullosa
Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study
A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families
Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
STAT3 targeting in dystrophic epidermolysis bullosa
Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study
A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families
Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa
Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)
Recessive dystrophic epidermolysis bullosa caused by a novel COL7A1 variant with isodisomy
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
STAT3 targeting in dystrophic epidermolysis bullosa
Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study
A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families
Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa